Hormone-Refractory Oncology Drug Market Report 2026

Hormone-Refractory Oncology Drug Market Overview

• Hormone-Refractory Oncology Drug market size has reached to $3.93 billion in 2025 • Expected to grow to $6.95 billion in 2030 at a compound annual growth rate (CAGR) of 12.1% • Growth Driver: Rising Prevalence Of Hormone-Resistant Cancers Driving Growth Of The Hormone-Refractory Oncology Drug Market Due To Long-Term Endocrine Therapy-Induced Resistance • Market Trend: Biomarker-Driven Targeted Therapies Transform Hormone-Refractory Oncology Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hormone-Refractory Oncology Drug Market?

Hormone-refractory oncology drugs are medications used to treat cancers that no longer respond to hormone therapy. These drugs target tumor growth through alternative biological pathways when hormonal control becomes ineffective. They are commonly applied in advanced or resistant cancer cases to slow disease progression and improve patient outcomes. The main drug types of hormone-refractory oncology drug include anti-androgens, aromatase inhibitors, estrogen receptor modulators, gonadotropin releasing hormone agonists/antagonists, and other drug types. Anti-androgens refer to therapeutic agents that block the action of androgens at receptor sites, helping to slow or inhibit the growth of hormone-sensitive cancer cells in refractory conditions. These solutions are based on therapy approaches such as monotherapy and combination therapy and they are administered through oral and injectable routes. They are various distributions such as hospital pharmacies, retail pharmacies, and online pharmacies and the various applications involved are prostate cancer, breast cancer, and other cancers.

What Is The Hormone-Refractory Oncology Drug Market Growth Forecast?

The hormone-refractory oncology drug market size is expected to see rapid growth in the next few years.It will grow to $6.95 billion by 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to growth in precision medicine and biomarker based oncology treatments, increasing development of next generation targeted cancer therapies, rising adoption of combination immunotherapy and small molecule drugs, expansion of personalized oncology treatment pathways in hospitals, increasing regulatory approvals for advanced refractory cancer drugs.Major trends in the forecast period include increasing adoption of targeted kinase inhibitors and next generation biologics for resistant cancer types, rising use of combination therapy approaches to overcome hormone resistance in oncology treatment, expansion of precision oncology enabling biomarker driven treatment selection for advanced cancers, growing development of immunotherapy based alternatives for hormone refractory cancer management, increasing shift toward oral oncology drugs for improved patient compliance in long term treatment.

Global Hormone-Refractory Oncology Drug Market Segmentation

1) By Drug Type: Anti-Androgens, Aromatase Inhibitors, Estrogen Receptor Modulators, Gonadotropin Releasing Hormone Agonists/Antagonists, Other Drug Types 2) By Therapy Approach: Monotherapy, Combination Therapy 3) By Route Of Administration: Oral, Injectable 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By Application: Prostate Cancer, Breast Cancer, Other Cancers Subsegments: 1) By Anti-Androgens: Non Steroidal Anti Androgens, Steroidal Anti Androgens, Second Generation Anti Androgens 2) By Aromatase Inhibitors: Non Steroidal Aromatase Inhibitors, Steroidal Aromatase Inhibitors 3) By Estrogen Receptor Modulators: Selective Estrogen Receptor Modulators, Selective Estrogen Receptor Degraders 4) By Gonadotropin Releasing Hormone Agonists / Antagonists: Gonadotropin Releasing Hormone Agonists, Gonadotropin Releasing Hormone Antagonists 5) By Other Drug Types: Androgen Biosynthesis Inhibitors, Targeted Kinase Inhibitors, Immunotherapy Agents

What Is The Driver Of The Hormone-Refractory Oncology Drug Market?

The increasing prevalence of hormone‑resistant cancers is expected to propel the growth of the hormone‑refractory oncology drug market going forward.Hormone‑Resistant Cancers are cancers that continue to grow or spread despite treatment with hormone‑blocking therapies, such as castration‑resistant prostate cancer (CRPC) or endocrine‑resistant breast cancer.The prevalence of hormone-resistant cancers is increasing due to prolonged exposure to endocrine (hormone) therapies, which drives tumor cells to adapt and develop resistance mechanisms over time.Hormone-refractory oncology drug development supports the management of these resistant disease states by providing targeted therapeutic options when conventional hormone therapies fail.For instance, in October 2025, according to NHS England, a UK-based publicly funded healthcare system, there were 354,820 new cancer diagnoses in 2023, which is 8,605 more than in 2022.Therefore, the increasing prevalence of hormone‑resistant cancers is driving the growth of the hormone‑refractory oncology drug market.

Key Players In The Global Hormone-Refractory Oncology Drug Market

Major companies operating in the hormone-refractory oncology drug market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S. A., Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Incyte Corporation, Ipsen S. A., Exelixis Inc., Arvinas Inc., Nuvation Bio Inc., Immunic Inc., Noxopharm Limited, Accutar Biotechnology Inc.

Global Hormone-Refractory Oncology Drug Market Trends and Insights

Major companies operating in the hormone-refractory oncology drug market are focusing on biomarker-driven targeted therapies that inhibit specific molecular pathways responsible for resistance to hormone therapy. Biomarker-driven targeted therapies refer to treatments designed to identify genetic alterations and selectively block signaling pathways that enable tumor growth after endocrine therapy failure. For instance, in November 2023, AstraZeneca, a UK-based pharmaceutical company, received U. S. Food and Drug Administration (FDA) approval for Truqap (capivasertib) for use in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations following disease progression. This therapy selectively inhibits the AKT signaling pathway and incorporates biomarker-based patient selection to improve treatment outcomes. The approval was supported by positive Phase III CAPItello-291 trial results demonstrating improved progression-free survival in patients with these genetic alterations, strengthening AstraZeneca’s oncology portfolio and expanding treatment options for patients with hormone-resistant breast cancer.

What Are Latest Mergers And Acquisitions In The Hormone-Refractory Oncology Drug Market?

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. Through this acquisition, Pfizer strengthened its oncology portfolio by integrating advanced antibody-drug conjugate (ADC) technologies, expanded its precision oncology capabilities to address treatment-resistant cancers, and enhanced its global market reach through a broader and more differentiated pipeline. Seagen Inc. is a US-based biotechnology company that develops targeted cancer therapies, with a core focus on antibody-drug conjugates designed to selectively deliver cytotoxic agents to tumor cells.

Regional Insights

North America was the largest region in the hormone-refractory oncology drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hormone-Refractory Oncology Drug Market?

The hormone-refractory oncology drugs market consists of sales of abiraterone acetate tablets, enzalutamide capsules, docetaxel injection, cabazitaxel injection, mitoxantrone injection, prednisone tablets, hydrocortisone tablets, and zoledronic acid injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

What is the Market Assessment and Strategic Outlook for the Hormone-Refractory Oncology Drug Industry?

The hormone-refractory oncology drug market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hormone-refractory oncology drug industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

What is the Market Assessment and Strategic Outlook for the Hormone-Refractory Oncology Drug Market Report 2026?

The hormone-refractory oncology drug market research report is one of a series of new reports from The Business Research Company that provides hormone-refractory oncology drug market statistics, including hormone-refractory oncology drug industry global market size, regional shares, competitors with a hormone-refractory oncology drug market share, detailed hormone-refractory oncology drug market segments, market trends and opportunities, and any further data you may need to thrive in the hormone-refractory oncology drug industry. This hormone-refractory oncology drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.